We examined the effect of combining aspirin and celecoxib in relation to UGT1A6 T181A and R184S variants among 1,647 patients in the Adenoma Prevention with Celecoxib ( APC ) trial who were stratified according to the use of low-dose aspirin after removal of adenomas and randomized to placebo , 200-mg twice daily , or 400-mg twice daily celecoxib for 3 years .